Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to -$372.2 million.

  • Iovance Biotherapeutics' Net Income towards Common Stockholders fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Net Income towards Common Stockholders stood at -$372.2 million for FY2024, which was up 16.18% from -$444.0 million recorded in FY2023.
  • Iovance Biotherapeutics' Net Income towards Common Stockholders' 5-year high stood at -$342.3 million during FY2021, with a 5-year trough of -$444.0 million in FY2023.
  • In the last 3 years, Iovance Biotherapeutics' Net Income towards Common Stockholders had a median value of -$395.9 million in 2022 and averaged -$404.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first declined by 15.67% in 2022, then increased by 16.18% in 2024.
  • Over the past 4 years, Iovance Biotherapeutics' Net Income towards Common Stockholders (Yearly) stood at -$342.3 million in 2021, then fell by 15.67% to -$395.9 million in 2022, then decreased by 12.16% to -$444.0 million in 2023, then increased by 16.18% to -$372.2 million in 2024.